Clinical trials: Rhinovirus

Rhinovirus

A Study of APL-10456-Vaccine

• Active, not recruiting
• Age: 18 years and older
• Early Phase 1
• Vaccines

AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of…

Trial name

NCT07399132

Testing

APL-10456-Vaccine

Where

2 sites in Australia

Volunteers

144 people, healthy volunteers welcome

Sponsor

Apollo Therapeutics Ltd